In episode 5 of ImmunoLogic, Michael T. Lotze, MD, discusses the evolution and future of tumor-infiltrating lymphocyte therapies.
Michael T. Lotze, MD
Advertisement
Professor of Surgery, Immunology, and Bioengineering, University of Pittsburgh; Department of Surgery, University of Pittsburgh School of Medicine
Articles by Michael T. Lotze, MD
Advertisement
Latest Updated Articles
ImmunoLogic, Episode 5: "Tumor Infiltrators and Triumphs: The Evolution of TIL Therapy" With Michael T. Lotze, MDPublished: July 30th 2025 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Quarter Century Update: Future Predictions for the Field
4
Quarter Century Update: What Does the Field Need Most Right Now?
5
